

General information about company	
Scrip code	524606
NSE Symbol	
MSEI Symbol	
ISIN*	INE508J01015
Name of company	BERYL DRUGS LTD
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2018
Date of end of financial year	31-03-2019
Date of board meeting when results were approved	07-08-2018
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	28-07-2018
Description of presentation currency	INR
Level of rounding used in financial results	Thousands
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	Pharmaceutical Industrty
Start date and time of board meeting	07-08-2018 18:00
End date and time of board meeting	07-08-2018 19:15
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2018	01-04-2018
B	Date of end of reporting period	30-06-2018	30-06-2018
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	41402	41402
	Other income	471	471
	Total income	41873	41873
2	Expenses		
(a)	Cost of materials consumed	21811	21811
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	4308	4308
(d)	Employee benefit expense	1908	1908
(e)	Finance costs	392	392
(f)	Depreciation, depletion and amortisation expense	1000	1000
(f)	Other Expenses		
1	Other Expenses	9930	9930
10			
	Total other expenses	9930	9930
	Total expenses	39349	39349

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2018	01-04-2018
B	Date of end of reporting period	30-06-2018	30-06-2018
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
3	Total profit before exceptional items and tax	2524	2524
4	Exceptional items	0	0
5	Total profit before tax	2524	2524
7	Tax expense		
8	Current tax	500	500
9	Deferred tax	0	0
10	Total tax expenses	500	500
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
14	Net Profit Loss for the period from continuing operations	2024	2024
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
17	Net profit (loss) from discontinued operation after tax	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
21	Total profit (loss) for period	2024	2024

Financial Results – Ind-AS			
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2018	01-04-2018
B	Date of end of reporting period	30-06-2018	30-06-2018
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Other comprehensive income [Abstract]			
1	Amount of items that will not be reclassified to profit and loss		
1	Amount of items that will not be reclassified to profit and loss	0	0
	Total Amount of items that will not be reclassified to profit and loss	0	0
2	Income tax relating to items that will not be reclassified to profit or loss		
		0	
3	Amount of items that will be reclassified to profit and loss		
1	Amount of items that will be reclassified to profit and loss	0	0
	Total Amount of items that will be reclassified to profit and loss	0	0
4	Income tax relating to items that will be reclassified to profit or loss		
		0	
5	Total Other comprehensive income		
		0	0

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2018	01-04-2018
B	Date of end of reporting period	30-06-2018	30-06-2018
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
23	Total Comprehensive Income for the period	2024	2024
24	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
25	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
26	Details of equity share capital		
	Paid-up equity share capital	50717	50717
	Face value of equity share capital	10	10
27	Details of debt securities		
28	Reserves excluding revaluation reserve		
29	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	0.399	0.399
	Diluted earnings (loss) per share from continuing operations	0.399	0.399
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0.399	0.399
	Diluted earnings (loss) per share from discontinued operations	0.399	0.399
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	0.798	0.798
	Diluted earnings (loss) per share from continuing and discontinued operations	0.798	0.798
30	Debt equity ratio	0	0
31	Debt service coverage ratio	0	0
32	Interest service coverage ratio	0	0
33	Disclosure of notes on financial results	Textual Information(1)	

Text Block	
Textual Information(1)	<ol style="list-style-type: none">1. The Quaterly results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 07th August 2018. The Statutory Auditors have carried out a limited review of the results for the quarter ended 30.06.20182. The Income from Operations is from one segment namely "Pharmaceutical Indusrty".3. Previous period exp. have been regrouped / rearranged, wherever necessary.4. Taxes and depreciation are calculated on proportionate to the annual estimated basis.5. These are Ind AS compliant financial result.6. Post the applicability of Goods and Services Tax (GST), with effect from 1 July 2017, revenue from operations are required to be disclosed net of GST.

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results		
Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2018	01-04-2018
Date of end of reporting period	30-06-2018	30-06-2018
Whether accounts are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
1 Segment Revenue (Income)		
(net sale/income from each segment should be disclosed)		
Total Segment Revenue		
Less: Inter segment revenue		
Revenue from operations		
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
Total Profit before tax		
i. Finance cost		
ii. Other Unallocable Expenditure net off Unallocable income		
Profit before tax		
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
Total Segment Asset		
Un-allocable Assets		
Net Segment Asset		
4 Segment Liabilities		
Segment Liabilities		
Total Segment Liabilities		
Un-allocable Liabilities		
Net Segment Liabilities		
Disclosure of notes on segments		

